Cholinergic receptor mutants of the nematode Caenorhabditis elegans. 1987

J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
Department of Biological Sciences, University of Missouri, Columbia 65211.

Potential acetylcholine receptor (AChR) mutants of the nematode are selectable by resistance to the neurotoxic drug levamisole, a probable cholinergic agonist. To determine which mutants may have achieved resistance through loss of levamisole receptor function, we have assayed mutant extracts for specific 3H-meta-aminolevamisole binding activity in the presence and absence of mecamylamine. We find that mutants in 3 of the 7 genes associated with extreme levamisole resistance are obviously deficient in saturable specific 3H-meta-aminolevamisole binding activity. Mutants of the 4 other genes have abnormal binding activities that fail to undergo the apparent allosteric activation of saturable specific 3H-meta-aminolevamisole binding activity caused by mecamylamine. Thus, all 7 genes appear to be required to produce a fully functional levamisole receptor. Mutants of several other genes associated only with partial resistance to levamisole have at least grossly normal receptor binding activities.

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D002107 Caenorhabditis A genus of small free-living nematodes. Two species, CAENORHABDITIS ELEGANS and C. briggsae are much used in studies of genetics, development, aging, muscle chemistry, and neuroanatomy. Caenorhabditides
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005796 Genes A category of nucleic acid sequences that function as units of heredity and which code for the basic instructions for the development, reproduction, and maintenance of organisms. Cistron,Gene,Genetic Materials,Cistrons,Genetic Material,Material, Genetic,Materials, Genetic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
February 1987, Molecular pharmacology,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
January 1979, Genetics,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
January 1977, Molecular & general genetics : MGG,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
October 1984, Science (New York, N.Y.),
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
June 1975, Genetics,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
January 1980, Molecular & general genetics : MGG,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
March 1986, Genetics,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
February 1984, Genetics,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
October 1978, Genetics,
J A Lewis, and J S Elmer, and J Skimming, and S McLafferty, and J Fleming, and T McGee
April 1985, Journal of neurogenetics,
Copied contents to your clipboard!